Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761924 | 1.00 | ADORA2A (0.74) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5761919 | 1.00 | ADORA2A (0.74) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5761694 | 0.96 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5763183 | 0.94 | ADORA2A (0.68) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5763305 | 0.93 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5761612 | 0.93 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5763303 | 0.93 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6329934 | 0.92 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5764526 | 0.92 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5764520 | 0.92 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1220862-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2006-03-22 | — | — | EP | claimed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | claimed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | claimed |
| EP-1220862-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2006-03-22 | — | — | EP | disclosed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20040209916-A1 | Combination therapies | PFIZER INC | 2004-10-21 | — | — | US | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
| US-6448236-B1 | FUNCTIONAL AGONISTS OF THE HUMAN ADENOSINE A2A RECEPTOR AND MAY BE USED AS, FOR EXAMPLE, ANTI-INFLAMMATORY AGENTS IN THE TREATMENT OF REPIRATORY DISEASES | PFIZER INC | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20040209916-A1 | Combination therapies | ADRA2C, ADRB2, ADRA2A | ADORA2A 10/4885ADORA3 13/4885ADORA2B 12/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.